In conclusion, our studies indicate that DC12 administration protects against MASH and reverses diet‐induced MASH by inhibiting mINDY and DNL, underlying a possible role of DC12 as a therapeutic option for the prevention and treatment of MASH. The gene discussed is HMCES; the disease is metabolic dysfunction-associated steatohepatitis.